Quest to introduce lab-developed test based on Augurex 14-3-3η (eta) biomarker to U.S. physicians later this month Vancouver, Canada – November 15, 2024 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it...
Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics. The new laboratory developed test, which uses Anti-14-3-3eta...
Augurex Life Sciences Corp. announces the launch of the 14-3-3η test by ARUP Laboratories, enhancing the early diagnosis and management of RA.The collaboration between Augurex and ARUP Laboratories highlights a mutual dedication to improving patient outcomes and...
Vancouver, BC – August 22, 2024 – Augurex Life Sciences Corp., a leader in biomarker-driven diagnostic solutions for the detection and management of autoimmune diseases, today announced its successful certification under the Medical Device Single Audit Program...
Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEOCo-Founder and outgoing CEO Dr. Norma Biln to helm research...
VANCOUVER, BC – Life Sciences BC (LSBC) is pleased to announce the recipients of the 26th Annual Life Sciences BC Awards presented by Farris. These awards recognize the exceptional achievements of individuals, companies, and organizations across British Columbia’s...
